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INTRODUCTION 
 
 Mesenchymal Tumors are the tumors arising from the connective tissue 
elements that support other tissues of the body, exclusive of epithelium, glia, 
reticuloendothelial system and supporting tissues of various parenchymal 
organs. They are divided into begin and malignant types. Treatment for benign 
lesions are relatively simple, in contrast to malignant type of mesenchymal 
tumours which depends on the stage of the disease that is vitally dependant on 
the histological grade of the tumour. 
 Further more the histology of the tumours is highly variable and often 
contrasting. 
 Controversy exists over the optimal diagnostic method for mesenchymal 
masses. 
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AIM OF THE STUDY 
 
To compare the usefulness and limitations of fine needle aspiration 
cytology, core needle biopsy and open biopsy with post operative full specimen 
biopsy, for mesenchymal tumours that are considered clinically as malignant. 
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REVIEW OF LITERATURE 
Definition 
 Mesenchymal tumours are those tumours which arise from the 
connective tissue elements which are supporting other tissues of the body 
exclusive of epithelium, reticuloendothelial system, glia and supporting tissue 
of various parenchymal organs. It is represented by the voluntary muscles, 
smooth muscles, fat bony tissue, fibrous tissue and peripheral nervous system. 
Embryologically, the tissue form the adhesive substance between various 
developing primitive connective tissue elements. 
Introduction 
 Mesenchymal tumours are highly heterogenous group of tumours that 
are classified on histo-genetic basis according to the adult tissue they resemble. 
They are divided into benign and malignant forms. 
 Begin mesenchymomas possess a limited capacity for autonomous 
growth and they closely resemble normal tissue. 
 Malignant mesenchymomas or sarcomas, in contrast are locally 
aggressive tumours that are capable of invasive or destructive growth, 
recurrence and metastasis. Unfortunately they term Sarcoma does not indicate 
the likelihood and rapidity of metastasis. For these reasons, it is important to 
qualify the term sarcoma with a statement, concerning the degree of 
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differentiation or the histological grade. Differentiation is a subjective term 
used to indicate the relative maturity of the tumour with respect to the normal 
adult tissue. Histological grade is a means of quantitating the degree of 
differentiation by applying a set of histological criteria. Usually well 
differentiated tumours are low grade lesions, whereas poorly differentiated 
tumours are high grade neoplasms. There are also borderline lesions in which it 
is difficult to determine the malignant potential and there are benign neoplastic 
and non neoplastic lesions that morphologically appear to be malignant, but 
follow a benign clinical course (Pseudo Sarcomas). 
INCIDENCE : Benign mesenchymomas outnumber malignant ones by a 
margin of about 100:1 in a hospital population. The incidence of malignant 
lesions varies in different age groups, different regions and also depends on the 
definition or malignant tumours and the types of neoplasms included among 
these tumours. 
 There seems to be an upward trend in the incidence of malignant 
mesenchymal tumours, but it is not clear whether this represents a true 
incidence or merely reflects better diagnostic capabilities. 
 They are common in old age as occurs in Carcinomas. About 15% 
affected are younger patients and about 40% affected are 55 years of age. 
Incidence is more common in males when compared to females. 
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ETIOPATHOGENESIS: 
 The etiopathogenesis of most mesenchymal tumours is still unknown. 
Recognized causes include various physical and chemical factors, exposure to 
ionizing radiation, and inherited or acquired immunological defect. 
a) Environmental factors: 
1. Environmental Carcinogens - Polycyclic Hydrocarbons 
2. Trauma or Post injury 
3. Chemical Carcinogens – Dioxin (TCDD) Vinyl chloride 
4. Ionising Radiation - Thorotrast 
b) Oncogenic Viruses: 
1. HIV – AIDS & Kaposi Sarcoma 
2. HTLV – III 
c) Immunological factors: 
1. Immuno deficiency 
2. Therapeutic Immuno Suppression 
3. Stewart – Treves Syndrome – Chronic lymphedema 
d) Genetic Factors: 
1. Neurofibromatosis 1 & 2 
2. Li – Fraumeni Syndrome (mutation of p53 gene) 
3. Retinoblastoma – Rb1 gene mutation 
4. Familial polyposis coli 
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5. Osler – Weber – Rendu syndrome 
CLASSIFICATION OF MESENCHYMAL TUMOURS 
 The classifications are based principally on the line of differentiation of 
the tumour. Each of the histological categories is divided into a benign and 
malignant group. Only malignant and intermediate groups will be considered 
here. 
I. Lipmatous tumours: 
a) Well differentiated type 
b) Myxoid type 
c) Round Cell (poorly differentiated) type 
d) Pleomorphic type 
e) Dedifferentiated type 
II. Fibrous tumours : 
a) Fibromatosis 
Superficial fibromatosis 
Deep fibromatosis 
i) Abdominal fibromatosis (Desmoid) 
ii) Extra abdominal 
iii) Intra abdominal 
iv) Mesenteric 
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v) Infantile (desmoid type) fibromatosis 
b) Malignant tumours 
Fibrosarcoma 
i) Adult 
ii) Congenital or Infantile 
iii) Inflammatory 
III. Fibrohistiocytic tumours: 
a) Intermediate tumors 
i) Atypical fibroxanthoma 
ii) Dermatofibrosarcoma protruberans 
iii) Giant cell fibroblastoma 
iv) Plexiform fibrohistiocytic tumours 
v) Angiomatoid fibrous histiocytoma 
b) Malignant tumours 
¾ Storiform – pleomorphic 
¾ Myxoid 
¾ Giant Cell 
¾ Xanthomatous 
IV. Smooth Muscle Tumours : 
¾ Leiomyosarcoma 
¾ Epitheloid leiomyosarcoma 
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¾ Myxoid type 
V. Skeletal Muscle Tumours : 
1. Rhabdomyosarcoma 
 Embryonal 
 Botyroid 
 Spindle Cell 
 Alveolar 
 Pleomorphic 
VI. Tumour of Blood and Lymph Vessels 
1. Intermediate Tumours 
 Haemangioendothelioma 
a) Epitheloid 
b) Endovascular papillary 
c) Spindle cell 
2. Malignant Tumours 
  a) Angiosarcoma and Lymphangio Sarcoma 
  b) Kaposi’s Sarcoma 
VII. Perivascular tumours: 
Malignant glomus tumour 
Malignant hemangiopericytoma 
VIII. Synovial tumours : 
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1) Synoviosarcoma  - a) Biphasic 
     b) Monophasic 
IX. Mesothelial tumours : 
1. Malignant Solitary Fibrous tumour of pleura and 
peritoneum 
2. Diffuse mesothelioma 
X. Neural tumours : 
1. Malignant peripheral nerve sheath tumour (mg. 
Schwannoma, NeurofibroSarcoma). 
a) Malignant Triton Tumour 
b) Glandular 
c) Epitheloid 
2. Malignant granular cell tumour 
3. Clear cell sarcoma 
4. Malignant Melanocytic Schwannoma 
5. Primitive neuro ectodermal tumours 
XI. Paraganglionic tumours: 
Malignant para ganglioma 
XII. Cartilaginous and Osseous tumours : 
¾ Chondro Sarcoma 
¾ Osteo Sarcoma 
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¾ Malignant Osteoclastoma 
¾ Fibrosarcoma  - From fibroblast 
- From periosteum 
¾ Malignant fibrous histiocytoma 
¾ Ewing’s Sarcoma 
¾ Reticulum cell sarcoma 
¾ Synovial sarcoma 
¾ Paget’s Sarcoma 
XIII. Miscellaneous Tumours 
¾ Alveolar soft part Sarcoma 
¾ Epitheloid Sarcoma 
¾ Malignant Extrarenal Rhabdoid Tumour 
¾ Desmoplastic Small cell tumour 
XIV. Unclassified tumours 
LIPOSARCOMAS:- 
 Liposarcomas are one of the most common sarcomas of adulthood and 
appear in the 40-60 years of age. Common sites – proximal extremities and 
retro peritoneum. Histologically they are divided into well differentiated, 
myxoid, round cell and pleomorphic variants. Well differentiated form show 
lipocytes and the other variants show lipoblasts. The behaviour of the tumour is 
  11
dependant on the histological nature of the tumour. Round cell and pleomorphic 
forms are aggressive and frequently metastasize. 
FIBROMATOSES :  
Superficial – Palmar, Plantar penile fibromatoses 
Deep fibromatoses (Desmoid Tumours) 
 Biologically lies in interface between exuberant fibrous proliferations 
and low grade fibrosarcomas. Deep seated fibromatoses are called Desmoid 
Tumours. They can occur at any age, but most frequent in 2nd to 3rd decades.  
 Desmoids are divided into extra abdominal, abdominal and intra 
abdominal. Extra abdominal desmoids occurs frequently in males principally in 
the musculature of shoulder, chest wall, back and thigh. Intra abdominal 
desmoids occur in mesentery (or) pelvic walls. Abdominal desmoids generally 
arise in the musculo aponeurotic structures of anterior abdominal wall, 
especially in women. Grossly appears as grayish white firm masses of 1 to 5 cm 
in greatest diameter. Histologically the centrally dense collagenous and 
peripherally plump fibroblasts are present. Multinucleate giant cells may be 
present. Frequently recurs locally after excision. Chemotherapy, radiotherapy 
and hormonal therapy are also useful. 
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FIBROSARCOMA: 
 It occurs commonly in retroperitoneum, then in thighs, knees and distal 
extremities. They are unencapsulated, infiltrative, soft, fish flesh masses with 
areas of haemorrhahge and necrosis histologically varying degrees of 
differentiation, from resemblance of cellular fibromas to highly cellular 
neoplasms with areas of necrosis, pleorphism, frequent mitoses and 
architectural disarray are seen. Herringbone fashion of arrangement may be 
seen. Recurring in more than 50% and metastasizing in 25% cases. 
 
MALIGNANT FIBROUS HISTIOCYTOMA: 
 Heterogeneous group of aggressive soft tissue tumour characterized by 
considerable cytologic polymorphism. The presence of bizarre multinucleated 
cells, Storiform architecture and a background of inflamed collagenous stroma 
with foamy macrophages. Grossly they are grey white unencapsulated masses, 
5 to 20 cms size. Types are myxoid, pleomorphic, inflammatory, giant cell and 
angiomatoid variants. Storiform – pleomorphic type is the most common type. 
Most variants of MFH are aggressive, recur unless widely excises. 
 
RHABDOMYO SARCOMA 
 Most common soft tissue sarcomas of childhood and adolescence. It 
occurs commonly in head & neck, then in urinary tract, extremities and trunk. 
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Grossly appears as grayish white to brownish fleshy masses. 
Rhabdomyosarcoma is histologically sub classified into embryonal, alveolar 
and pleomorphic variants. Embryonal type includes sarcoma botryoides and 
spindle cell variants. Rhabdomyoblasts with cross striation may be present. 
Rhabdomyo Sarcoma are aggressive neoplasms and usually treated with a 
combination of surgery and chemotherapy with or without radiation. The 
histologic variant and location of the tumour influence survival. Botryoid 
subtype has better prognosis. 
 
LEIOMYO SARCOMA 
 They account for 10% to 20% of soft tissue sarcomas. Male female ratio 
is equal. Mostly arise from skin and soft tissues of extremities and 
retroperitoneum and achieve large size. They consist of numerous capillary 
channels enclosed within nests of spindle shaped cells – pericytes. The tumor 
may recur and as many as 50% metastasize to lungs, bone and liver; Regional 
lymphnodes are also affected. 
KAPOSI’S SARCOMA 
 Sarcoma commonly associated with AIDS. Clinically four forms occur : 
- European, African, Transplant associated and AIDS associated. Clinically, 
picture varies from multiple red to purple skin nodules or plaques to large 
spongy confluent lesions. In disseminated disease, mucosal surface, lymph 
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nodes, salivary glands and viscera are involved. Microscopically pulmp, spindle 
shaped, stromal cells containing spaces filled with RBCs and lined by 
recognizable endothelium. Growth factors released by HIV infected 
lymphocytes induce the proliferation of Kaposi’s sarcoma spindle cells. 
HAEMANGIO ENDOTHELIOMA: 
 Hemangio endothelioma represent an intermediate grade between the 
well defined haemangiomas and frankly anaplastic angiosarcomas. Most 
frequenly encountered in skin, but may affect spleen and liver. Histologically, 
vascular channels are evident, with masses and sheets of spindle shaped cells 
with mitotic figures and some pleomorphism. 
 Epitheloid hemangio endothelioma, unique vascular tumour occurring 
around medium sized and large veins in the soft tissues of adults. 
 
SYNOVIAL SARCOMA 
 It accounts for 10% of all soft tissue sarcomas and 4th most common 
sarcoma. Mostly occurs in 20-40 years of age: majority develop in the vicinity 
of large joints of extremities, especially lower extremities around knee joints an 
thigh. Uncommonly parapharyngeal region and abdominal wall are involved. 
 Histologic hallmark is biphasic morphology of tumour cells (epithelial 
like cells and spindle cells). The tumour cells do not have the features of 
synoviocytes despite its mimicry as synovium. Most synovial sarcomas are 
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monophasic. Calcified concretions may be seen. Immuno histochemically reacts 
for Keratin, epithelial membrane antigen, differentiating from other sarcomas. 
 They are treated aggressively with limb sparing therapy. Commonly 
metastasize to lymphnodes, lung and skeleton. 
MALIGANT PERIPHERAL NERVE SHEATH TUMOUR: 
 They arise denovo or following radiotherapy from transformation of a 
plexiform neurofibroma, the fact provides the basis for their association with 
neurofibromatosis type I. The lesions are poorly defined tumour masses with 
frequent infiltration. Necrosis is commonly present. Microscopically, tumour 
cells may resemble schwann cells with elongated nuclei and prominent bipolar 
processes. Mitosis, necrosis and extreme nuclear anaplasia are common. 
Tumour cells may be immuno reactive to S.100 protein. Highly malignant 
sarcomas, locally invasive, frequently lead to recurrence and metastatic spread. 
 
CHONDROSARCOMA: 
 Chondrosarcomas are the second most common malignant matrix 
producing tumours of bone. They arise commonly in axial skeleton, and rarely 
in long bones. Age group affected commonly is above forty years M:F = 2:1 in 
younger age group, clear cell and mesenchymal variants are common. 
 It can occur from preexisting enchondroma, osteochondroma, 
chondroblastoma, fibrous dysplasia or paget’s disease. Histologically classified 
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as conventional (hyaline, Myxoid), clear cell, differentiated, mesenchymal and 
dedifferentiated variants. Grossly, large bulky tumours made up of greywhite 
nodules with glistening tissue having viscous and gelatinous ooze from cut 
surface. Grading done by cell morphology, cellularity and mitosis. Most of the 
lesions are of grade I & II. Classifications may be present among the foci of 
cartilaginous matrix. Tumours more than 10cm mostly behave aggressively. 
Chondrosarcomas metastasize preferentially to the lungs and skeleton. Most of 
the tumours are treated by wide surgical excision, the mesenchymal and 
dedifferentiated tumours are treated in addition with chemotherapy, due to their 
aggressive clinical course. 
 
STAGING AND GRADING OF MESENCHYMAL TUMOURS 
 Staging provides short hand information regarding the state or extent of 
the disease at a particular designated time, preferably at the time of initial 
histological diagnosis. 
 Grading determines the degree of malignancy and is based on an 
evaluation of several histological parameters like 
a) Degree of cellularity 
b) Cellular polymorphism or anaplasia 
c) Degree of necrosis 
d) Expansive or infiltrative and invasive growth. 
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Additionally, also by amount of matrix formation, presence or absence 
of haemorrhage, calcification and inflammatory infiltrate. 
The limitations and pitfalls of grading systems vary as 
1) The significance and predictive values of various histological parameters 
differ in various types of sarcomas. 
2) Recurrent lesions after therapy shows a higher degree of differentiation 
than primary tumours. 
MESENCHYMAL TUMOURS 
 DEFINITION OF GRADING PARAMETERS 
PARAMETER       SCORE 
I. Degree of tumour differentiation : 
a) Close resemblance to normal adult tissue   1 
b) Tumour type clearly      2 
c) Tumour type uncertain      3 
 
II. Tumour necrosis 
a) No tumour necrosis on any slide    0 
b) Less than 50% Tumour necrosis    1 
c) More than 50% tumour necrosis    2 
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III. Mitotic count 
a) 0-9/per 10 Hpf       1 
b) 10-19/per 10 Hpf       2 
c) 20 + / per 10 Hpf       3 
HISTOLOGICAL GRADE     Total 
Score 
Grade I        2,3 
Grade II        4,5 
Grade III        6,7,8 
 
STAGING SYSTEMS 
I. ENNEKING SYSTEM : Anatomical presentations: 
 T1  - Intra compartmental tumours confined within the boundaries of 
well defined anatomical structures. 
 T2 – Extra compartmental neoplasms that arise within or involve 
secondarily extrafascial planes or spaces that have no natural anatomical 
barriers for extension. 
 Grades :  Grade I - Low grade 
   Grade II - High grade 
 Stages : Stage I - Low grade tumours without metastasis 
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  Stage II - High grade tumours without metastasis 
  Stage III - Lesions of either grade with metastasis. 
 Each of these stages is sub classified to the anatomical presentation of 
the lesion (T1 to T2) 
 A – Signifies intra compartmental lesions 
 B – Signifies extra compartmental lesions. 
II AMERICAN JOINT COMMITTEE (AJC) Staging System 
 It is the commonly followed system universally. It uses  
1) The size and extension of the primary tumour (T) 
2) The involvement of lymph nodes (N) 
3) The presence of metastasis (M) 
4) The type and grade of the tumour (G) 
AJCC STAGING OF MESENCHYMAL TUMOURS 
Definitions of TNMG 
 T : Primary Tumour 
T1 – Tumours less than 5cm 
T2 – Tumour 5 cm or greater 
N  : Nodal status 
N0 – No histologically verified metastasis to regional lymph nodes. 
N1 – Hisotlogically verified regional lymph node metastasis 
M : Distant metastasis 
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M0- No Distant Metastasis 
M1-Distant metastasis 
G – Historigical grade of malignancy 
G1 – Low (Well differentiated) 
G2 – Moderate (moderate differentiated) 
G3 – High (poorly differentiated) 
G4 – Undifferentiated 
 
 
AJC STAGING OF MESENCHYMAL TUMOURS : 
Definition of stages  
 Stage I  - State Ia - (G1T1N0M0) 
  1  Stage Ib - (G1T2N0M0) 
 Stage II - Stage IIa - (G2,T1,N0M0) 
    Stage IIb - (G2,T1,N0M0) 
Stage III - Stage IIIa - (G3,4T1N0M0) 
    Stage IIIb - (G3,4T2N0M0) 
Stage IV  - Stage IVa - (G1-4T1-2N1M0) 
  - Stage IVb - (G1-4 T1-2 N0-1 M1) 
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ADVANTAGES AND DISADVANTAGES OF STAGING SYSTEM 
Enneking  System: 
 Advantages: 
1) Best suited for well documented mesenchymal tumour arising in 
extremities as emphasis on compartmentalization is given. 
2) Retrospective staging not possible 
3) Two tier grading system, too narrow for wide biological range of 
mesenchymal tumours. 
 
AJCC Staging: 
Advantages : 
1) Universally acceptable 
2) Individual details like type, size and depth of tumour addressed 
3) Grading sufficiently given importance 
4) Retrospective staging possible 
Disadvantages : 
1) Greater complexity of the system. 
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Management of Algorithm for Malignant Mesenchymal tumours  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BRT – Brachy Radio Therapy 
ERT – External Radio Therapy 
 
 For unresectable tumours, either preoperative radiotherapy or 
chemotherapy is used. 
Evaluation Suspected Diagnosis Etiological Factors 
Coreneedle biopsy 
High Grade Histopathology Low Grade 
Stage 
>10cm Wide Resection >5cm 
BRT / ERT 5-10cm ERT <5cm 
BRT. + / - ERT Follow Up Consider 
Chemotherapy 
Pre-op/Pose op. 
  23
SURGICAL TREATMENT: 
 Resection of the lesion carried out with a clearance of 2cms in all 
dimensions along the uninvolved tissue and the procedure called according to 
the amount of resection namely local excision, wide excision, compartmental 
excision and amputation. 
Amputation should be reserved only for those tumours not able to be resected 
by any other means. Amputation should be performed one joint above the 
lesions because intra – medullary spread of the tumours is common. Local 
recurrence is common in those undergoing limb sparing surgery with irradiation 
compared to that of amputation.  
ADJUVANT CHEMOTHERAPY  : Preoperative 
        Postoperative 
Drugs used are : 1) Cyclophosphamide 700 – 1000mg/m2 
   2) Doxo rubicin 50 to 70 mg/m2 
   3) Vincristine – 1.6 to 2mg/m2 
   4) Methotrexate 50 to 250mg/m2 
 Other drugs used include – Ifosfamide, Dacarbazine and Carboplatin. 
INTRA ARTERIAL CHEMOTHERAPHY: 
1) Intra arterial infusion of chemotherapeutic 
agents with or without tourniquet is used. 
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2) Most commonly used agents – Doxo rubicin 
3) Continuous infusion over 1 to 10 days via a 
percutaneouly placed cather is used 
4) Complications include 
i. Arterial thromboembolism 
ii. Necrosis and pain 
iii. Infection 
iv. Delayed wound healing 
PRE OPERATIVE CHEMOTHERAPY: 
It is used for the following purposes 
a) To avoid radical resection 
b) To limit the spread of tumour at the time of operation 
c) Occult micro metastasis would be dealt with pre-operatively 
d) Agents used include – Cyclophosphamide, vincristine, Doxorubicin, 
Dacarbazine and Ifosfamide. 
Adjuvant and Pre-Operative Radiotherapy 
 For advanced and unresectable tumours preoperative radiotherapy in the 
form of Brachy therapy or external beam radiation therapy is used. It is useful 
for the shrinkage in the size of the tumour and also for the reduction in the 
vascularity so that surgery becomes easier. 
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 Intra operative radiotherapy (IORT), for Retroperitoneal sarcomas is 
available. Dose usually used is 20 Gy. For head and neck sarcomas, post 
operative adjust external beam radiation is used. 
Role of Hyperthemia: 
 Whole body hyperthermia achieved with extracorporeal heating of blood 
has been combined with chemotherapeutic agents like Ifosfamide and 
carboplatin, is used in the management of Soft tissue Sarcomas. 
 
PROGNOSTIC FACTORS: 
Factors increasing the risk of local recurrence 
1) Age more than 50 years 
2) Recurrent disease at the time of presentation 
3) Positive histologic primary margins 
4) Histologic subtupes of fibrosarcoma including desmoids. 
Factors increasing the risk of distant metastasis 
1. Tumour size greater than 5cm 
2. Histologic high grade 
3. Deep location of the tumour 
4. Recurrent disease at the time presentation. 
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FINE NEEDLE ASPIRATION CYTOLOGY 
 
 For a diagnosis of mesenchymal tumours successful FNAC smear is to 
be obtained and it must be correctly done with utmost caution. Otherwise the 
false negative results will be high even in the hands of experienced clinicians. 
Materials 
1. Spirit (or) any lodine based antiseptic solution. 
2. Cytofix, which contains absolute alcohol as the main 
constituent. 
3. Microscopic slides of 76mm x 26mm size, with frosted ends 
for labeling patients name and number, in pencil. 
4. Sterile disposable 10ml Syringe with 23 or 24 G needle (with 
outer diameter of 0.6mm, 2.5 cm in length). 
5. Patinet’s clinical details to be filled up in laboratory 
requisition form. 
6. Transport box. 
 
METHODS: 
 For FNAC, no anaesthesia is necessary. The paitents should be 
thoroughly explained of the procedure to be done and consent to be obtained for 
the same. An antiseptic solution should be used to clean the skin over the 
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swelling. The lump is located and firmly held between the thumb and index 
finger of free hand. The needle is pushed into the mass delicately by an oblique 
track, perceiving the tissue texture on entry and penetration. Plunger of the 
syringe is retracted creating a negative pressure. Without loosing the pressure or 
pulling the needle tip out of the skin the whole syringe is rotated and gently 
moved in & out. Maintain the negative pressure continuously. The cells are 
sucked into the lumen of the needle. Now slowly release the pressure on the 
plunger. With draw the syringe and needle gently from the skin. Pressure is 
exerted over the puncture site with a cotton wool. 
 
Expelling the biopsy material: 
 After disconnecting the needle from the syringe, fill the syringe with air. 
Replace the needle firmly. The syringe should be held vertically with the needle 
tip above the surface of the microscope slides. 
 Push the plunger down carefully with force. Now the contents extracted 
from the swelling are sprayed over the slides. The process may be repeated for 
another few times also. 
 
Preparation of slides: 
 The tissue fluid that is sprayed over the microscope slides after being 
blown by the syringe, is allowed to dry in air for 3-5 minutes. Cytofix solution 
(absolute alcohol based solution) is used to fix the smear. The smear must be 
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fixed before air drying, when papanicolaou stain is used. Then the slides are 
carefully labeled and sent to the laboratory. 
 
Fixatives and Fixation: 
 A number of fixatives are used in cytology. The common ones are 
modifications of 95% ethyl alcohol. It alone can be used with satisfactory 
results but addition of 3% glacial acetic acid increases the nucleoprotein fixing 
properties. This is a standard fixative and gives excellent nuclear and 
cytoplasmic morphology. 
 Fixation doesn’t require more than five minutes but a minimum of 10 to 
15 minutes is advisable for proper adhesion of the smear to the slide. If 
necessary, smear must be kept in the alcohol or other solution over a long 
period of time. Smears which are to be mailed to the laboratory for staining 
should be fixed in alcohol – ether for atleast one hour. If ether is not available, 
95% ethyl alcohol alone can be used. Methyl or even isopropyl alcohol can be 
used as substitutes even though they are less desirable. 
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CORE NEEDLE BIOPSY 
 The procedure of core needle biopsy is a minor surgical procedure and it 
must be performed with utmost caution and precautions of a surgical procedure, 
to obtain the maximum possible amount of tissue for Histopathological 
examination of the lesions.  
Materials 
1) Spirit swabs and lodine based antiseptic solutions 
2) Disposable needle of 23 or 24G size 
3) Coreneedle biopsy (Tru – Cut) needle (25cm x 2.5mm size) 
4) Diposable 2ml syringe 
5) Bottles containing 10% formalin 
6) No:11 – Surgical blade. 
7) 2% Lignocaine solution 
8) Patients clinical details to be filled up in laboratory requisition form. 
Methods: 
 For coreneedle biopsy, local anaesthesia is used. The procedure to be 
done is explained to the patient and consent obtained. The site of the swelling is 
thoroughly cleansed with iodine preparations and then the spirit. The elected 
site has to be exposed under good light after taking all aseptic precautions. The 
site is infiltrated with 0.5ml of 2% xylocaine and 7-10 minutes to be allowed 
  30
for achieving local anaesthesia. Then with No.11 blade a small incision of less 
than 5mm is made. The coreneedle biopsy needle is pushed into the mass gently 
by an oblique track. Through the incised site the plunger is advanced and held 
firmly. Then the cutting edge of the needle advanced, thereby harvesting the 
tissue that has taken up in the slot provided. 
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OPEN BIOPSY 
It is of two types : Excisional biopsy and Incisional biopsy. 
1.  Excisioal Biopsy: It refers to removal of entire grossly evident lesions, 
usually with significant margin of normal tissue, excisional biopsy should be 
reserved for lesions less than 3 to 5cm in diameter or for very superficial 
tumours. Excisional biopsy of large or deep tumours are undesirable since they 
can contaminate surrounding tissue planes. And this may compromise the 
subsequent definitive surgical procedure. 
2.  Incisional Biopsy: It is the appropriate technique for diagnosing most 
soft tissue masses. This technique involves the removal of a generous wedge of 
tissue, which is minimally manipulated at the time of surgery. 
1. For extremity lesions, the incision should be oriented along the long axis of 
the extremity. 
2. For Truncal or retroperitoneal lesion, the biopsy incision should be situated 
in such a way that it can be readily excised along the tumour, if a Diagnosis of 
malignancy is made. 
3. The biopsy site should be directly over the tumour, at the point where the 
lesion is closest to the surface. 
There should be no raising of flaps or disturbances of tissue planes superficial 
oto the tumour. 
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5. Perfect haemostasis has to be obtained; to prevent hematoma, which could 
disseminate tumour cells through normal tissue planes. 
6. No drain should be kept 
7. In case when a drain is mandatory, it should exit either through or very near 
the biopsy incision. 
8. If malignancy is proved, the drain tract must be excised in continuity with 
tumour tissue. 
 Open biopsy yields the exact, histologic type of tumour, grade of the 
tumour and the specimens obtained through open biopsy often are sufficient 
enough to subject the tumour to ancillary studies like Immunohisto chemistry 
cytogenentics and flow cytometry. 
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STAINING PROCESS IN FNAC 
 For routine wet fixation with ethanol and staining by papanicolaou 
technique, standard Eosin – Haematoxylin methods are used. Both these 
methods make use of Harris heamatoxylin. 
 Romanowsky stain (ie) Giemsa or May grun wald – Giemsa may be 
used. 
 ‘DIFF QUIK’ – rapid staining method can also be used when 
preoperative FNAC is performed and immediate diagnosis is required. 
EOSIN: 
 To demonstrate the general histological architecture of a tissue, eosin is 
the most suitable stain in combination with an alum haematoxylin. It is of 
particular value in its ability to distinguish proper differentiation between the 
cytoplasm of different types of cells. The eosins are xanthine dyes and the 
following are easily available eosins commercially. 
a) Eosin – B  (ie Eosin blue) 
b) Eosin –Y   (ie Eosin yellow) 
c) Ethyl Eosin (ie Eosin alcohol solution) 
 Of these, Eosin –Y is the most widely used and even though it is water 
soluble, it is satisfactorily soluble in alcohol also. It is usually used as 0.5% to 
1% solution in distilled water with a crystal of thymol added to inhabit the 
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growth of fungi. It is used as a cytoplasmic stain. In order to sharpen the 
staining, a little acetic acid is added. Differentiation of eosin staining occurs in 
sufficient tap water wash and further differentiation occurs during dehydration 
through alcohol. The intensity of eosin staining and the degree of differentiation 
required is largely a matter of individual pathologist’s choice. 
Harris Haematoxylin: 
 This is an alum haematoxylin which is chemically ripened with mercuric 
oxide. It gives clear nuclear staining and for this reason, it has been used in the 
diagnostic cytology with eosin as a counter stain. In cytology. Harris 
haematoxylin is used as a progressive stain but in routine histological use, it is 
used regressively.  
 
The constituents are: 
 Haemotoxylin - 2.5gm 
 Absolute alcohol - 25ml 
 Potassium alum - 50gm 
 Distilled water - 500ml 
 Mercuric oxide - 1.25gm 
 Glacial acetic acid - 20ml 
 The haematoxylin is dissolved in absolute alcohol, then added to alum 
which has been previously dissolved in warm distilled water in a two litre flask. 
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The mouth is rapidly brought to the box and the mercuric oxide is then added. 
By plunging the flask into cold water or into a sink containing ice, the stain is 
rapidly cooled. Then, the acetic acid is added and the stain is ready for 
immediate use. Addition of glacial acetic acid gives more precise and selective 
staining of the nuclei. 
Papanicolaou Technique of Staining: 
 This is the method of choice in cytology. Because it gives a dependable 
nuclear morphology with clear translucent demonstration to the cytoplasm. For 
this the following stains are to be prepared. 
a) Harris haematoxylin 
b) OG – 6 
c) EA -50 
The following are the results obtained after staining 
 Nucleus  - blue to black 
 Cytoplasm - Pink to green 
 RBC  - Orange to red 
 Fibrin  - Deep pink 
Haematoxylin and Eosin Staining:  
This technique is not superior to papanicolaou technique for clarity and 
detail, but many cytopathologists use this method because they are already 
familiar with this type of staining on histological section. 
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STAINING PROCESS FOR HISTOPATHOLOGICAL EXAMINATION: 
 The specimen of tissue obtained by core needle biopsy, following 
fixation with 10% Formalin, is subjected to various procedures. 
1) Fixation  
2) Tissue processing - Dehydration 
-  Clearing 
- Wax Impregnation 
3) Embedding 
4) Section cutting using microtome 
5) Staining 
Staining Procedure: 
 Staining procedure commonly adopted is by using Haematoxylin and 
Eosin Staining. Special Stains like verhoff stain, van gieson stain, and Komori’s 
stain are also used. 
Results: 
 Muscle, Keratin, Elastic fibres - Bright red 
 Collagen, reticulin   - Pink 
 RBCs     - Orange 
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CYTO DIAGNOSTIC CRITERIA FOR DIAGNOSIS OF MALIGNANCY 
a) Structural changes in cells and nuclei 
b) Changes in inter – relationship of cells 
c) Indirect diagnostic criteria. 
I) Structural changes in cells: 
 1. Cytoplasmic changes : 
  a) Cytoplasmic inclusion bodies 
  b) Marked basophilia 
  c) Atypical vacuolation 
 2. Nuclear changes: 
  a) Hyper chromasia 
  b) Increased nuclear cytoplasmic ratio 
  c) Abnormal and increased mitotic figures 
  d) Enlarged and increased number of nucleoli 
e) Structural abnormalities like loculation, elongation or 
indentation of nucleus. 
 3. Changes in the cell: 
  a) Enlargement of cells 
  b) Aberrant forms 
II Changes in the inter – relationship of cells 
a) Loss of polarity 
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b) Anisocytosis 
c) Lack of distinct cell boundaries 
d) Engulfment of one cell by another. 
 
III. Indirect diagnostic criteria: 
a. Prominance of histiocytes 
b. Excess of lymhocytes 
c. Presence of red blood cells. 
 
CYTOLOGICAL REPORTING 
 Cytology reporting consists of four categories of cells 
 
I. Presence of Benign cells: 
 FNAC smear shows acute and chronic inflammatory cells and 
degenerated epithelial cells – No malignant cells was seen. 
 
II. Presence of malignant cells: 
 The smear shows pleomorphic, hyperchromatic malignant epithelial cells 
with variations in the nuclear cytoplasmic ratio. 
 A define cytological diagnosis of cancer should be based on the 
predominance of unmistakable cancer cells and on the presence of a few 
scattered suspicious cells among normal cells. More information about the 
grade and differentiation of the tumour cannot be obtained. 
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III No epithelial cells seen 
 The smear may show eosinophilic material, and a few inflammatory cells 
or adipose tissue. This is due to unsatisfactory smear preparation. 
 
IV Presence of suspicious malignant cells: 
 If the specimen is very scanty or the specimen is cellular and suggest a 
well differentiated malignancy but not clear cut enough to submit the patient for 
definite treatment for cancer. The aspiration should be repeated and if necessary 
a biopsy recommended. 
 
HISTOPATHOLOGICAL CRITERIA FOR MALIGNANCY: 
a) Structural changes in cells and nuclei 
b) Changes in the interrelationship of cells 
c) Alteration of tissue architecture 
d) Invasion of adjacent structural elements. 
 
Structural changes in cells and nuclei and changes in interrelationship of 
cells are noted in a similar manner, as followed for FNAC study. However the 
HPE of the specimen, for giving the needed information relies upon the 
alteration of tissue architecture within the site of origin and in surrounding 
structures near by the origin and also on the invasion of adjacent structures 
namely capsular invasion, vascular and lymphnodes invasion. 
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HPE report carries the following entities: 
1. Histologic type of the tumour 
2. Grade of the tumor – I, II and III 
3. Size of the tumour – Cm in greatest diameter. 
4. Location  - subcutis, muscle, body cavity 
5. Margins  - Positive, negative (if less than 1cm, give 
measurement) 
6. Necrosis   - <15%, >15% 
7. Invasion  - Lymphatic and vascular invasion 
8. Ancillary studies – State if tissue was sent. 
For cytogenetics, molecular diagnostics follow cytometry or tissue banking.  
 
 
 
 
 
 
 
 
 
 
  41
MATERIALS AND METHODS 
Selection of cases: 
 In this study, 50 patients who presented with swellings arising from soft 
tissue and bony regions with clinical suspicion of malignancy were selected 
randomly among those patients who got admitted in general surgery, orthopedic 
surgery and surgical oncology wards of Government Rajaji Hospital, Madurai. 
The cases were studied from October 2005 to October 2007. For all patients, 
representative samples were obtained by FNAC, core needle biopsy and in 
some cases, by open biopsy and sent for patholgocial examination. 
 In this study, only those tumours which are having high clinical 
suspicion of malignancy were selected. Benign appearing soft tissue and bony 
tumours were excluded from the study. Selection of patients was randomy done 
irrespective of age and sex. The age group of patients varied from 1 year to 70 
years. 
 When diagnosis was obtained with core needle biopsy, in most of the 
cases open biopsy was deferred and was proceeded with definitive procedure. 
 On the day of admission, bleeding time & clotting time were checked. 
For all the subjected patients, tetanus prophylaxis also was given. 
 In all the patients subjected, simultaneously both the FNAC, and core 
needle biopsy was done and the samples were sent for pathological analysis 
  42
when the results are negative, inconclusive (or) not helping for grading of the 
tumour, open biopsy (Incisional or excisional) was resorted to. 
 All the tumours that have been biopsied by FNAC, Core needle biopsy 
or open biopsy were subjected to surgical procedures. The specimen excised 
also sent for HPE. 
 The results obtained from FNAC, coreneedle biopsy and open biopsy 
technique were compared with the results of the postoperative HPE. 
 Out of 50 cases studied, 46 cases were newly detected cases and 4 cases 
were recurrent lesions. 
PROCEDURE ADOPTEID IN THE SUTDY: 
 FNAC: Fine needle aspiration was done with 10ml. disposable plastic 
syringe with 23 G needle. 
 An antiseptic solution was used for thorough cleaning of skin over the 
mass and the needle aspiration was done. Once the cells were dispersed on the 
slide, they were fixed with cytofix solution. The slides were sent to the 
pathology department after labeling. To have a detailed cytological study, 
aspiration was done from multiple sites and several slides were prepared. 
 
Coreneedle biopsy:- 
 Following similar aseptic precautions, under local anaesthesia after 
making a small skin incision of 0.5 cm size, core needle biopsy done in multiple 
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planes with 14G biopsy needle with a slot of 2.5cm length. After withdrawing 
the needle the site was compressed to arrest possible hemorrhage. The samples 
were placed in bottles containing 10% formalin and sent for HPE. 
Complications: 
 No major complications encountered in this study. For few vascular 
tumours like Angiosarcoma, slight haemorrhage was encountered after the 
biopsy procedure which was controlled by external compression for five 
minutes. Other wise all the procedures done in this study were uneventful. 
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OBSERVATIONS AND ANALYSIS 
 
 50 patients with mesenchymal tumours that are clinically appearing 
malignant are studied. 
 
 Out of which, male cases were 32 and female were 18, M:F= 1.66:1 
Most of the patients were falling into the age group of 30 to 50 years. 
 
 Most of the commonly encountered mesenchymal tumours were 
aggressive fibromatosis, which constituted about 20% of total cases. The 
following is the composition of various tumours in the study. 
 
 Aggressive Fibromatosis  - 20% 
 Chondrosarcoma   - 12% 
 Malignant fibrous histiocytoma - 12% 
 Synoviosarcoma   - 12%  
 Fibrosarcoma   - 8% 
Rhabdomyosarcoma    - 8% 
Malignant peripheral nervesheath    
Tumours     - 8% 
Ewing’s Sarcoma    - 2% 
Angiosarcoma    - 6% 
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Malignant Hemangioendothelioma - 4% 
Malignant Hemangio Pericytoma  - 4% 
Desmoid Tumour    - 4% 
 
The tumours commonly present in lower extremities (54%) followed by 
Trunk (24%), upper extremities (12%) Head and Neck (4%) and abdomen(6%). 
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COMPARISON OF RESULTS OBTAINED BY VARIOUS 
MODALITIES OF BIOPSY IN MESENCHYMAL TUMOURS 
 
I REGARDING YIELD OF DIAGNOSIS: 
 a) FNAC   - Positive in 26 cases (52%) 
- Negative in 24 cases (48%) 
 b) Coreneedle biopsy - Positive in 46 cases (92%) 
- Negative in 4 cases (8%) 
 c) Open biopsy/ Postoperative biopsy - Positive in all cases. 
II REGARDING YIELD OF GRADING OF TUMOUR 
 a) FNAC   - No grading possible 
 b) Core needle biopsy - Yield grading in 90% cases 
 Grade I  - 45% 
 Grade II  - 10% 
 Grade III  - 45% 
 c) Open biopsy/ 
 Post operative biopsy - Grade obtained in all cases 
P.Value between FNAC and Coreneedle Biopsy for yield of diagnosis is 
0.00023 (Significant) 
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DISCUSSION 
 As per literature, benign mesenchymal tumours out number malignant 
tumours by 100:1 in a hospital population and malignant mesenchymal tumours 
are commonly found in old age. 40% of affected are above 55 years of age. 
 Incidence is more common in males when compared to females, M:F = 
1:5:1. They arise commonly from the extremities, followed by chest wall, 
mediastinum and retroperitoneum. 
 In my study, the incidence of malignant mesenchymal tumours is about 
0.5% of the total admissions is surgical wards. 
 The age group commonly affected is between 30-50 years of age. 
 Incidence in males out numbered females by ratio of 1.66:1. 
 The site commonly involved is lower extremities (54%), followed by 
Trunk (24%) upper extremities (12%) Head and Neck (4%) and abdomen (6%). 
1. In 1982, mankin et al evaluated 329 patients with malignant 
mesenchymal tumours, found FNAC to yield positive value in 76%, and 
concluded as grading could not be detailed, as sampling errors is high 
and found coreneedle biopsy to be yielding positive diagnostic results in 
95% and grading rate was about 86%. 
2. In 1992, Barth R.J. et al conducted a prospective study of value of 
corneedle biopsy and FNAC in diagnosis of soft tissue masses, and 
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concluded that coreneedle biopsy yielded positivity in 98% and FNAC in 
94% granting of  the tumour was obtained in 90% of the cases by 
coreneedle biopsy and not possible by FNAC. 
3. However, in 1999, a study conducted by Kilpatrick et al, showed that 
diagnosis of the type of mesenchymal tumours and grading of the 
tumours can be obtained upto 92.5% in FNAC. 
In my study, of the 50 cases studied. FNAC reveals the positive pathological 
diagnosis of tumour and its type in 52% of cases and was negative and 
inconclusive in 48% of cases. It was found not to have any help in grading of 
the tumour with the available facilities. 
In contrast, coreneedle biopsy yielded positive pathological nature of the 
tumour and its types in 92% of cases, and was negative in 8% cases. Also it 
gave positive results in grading of tumours in 90% of cases, which can be 
comparable to other studies that have been conducted in the past. Open 
biopsy/post operative biopsy revealed the exact nature of diagnosis and grade of 
the tumour in all cases. 
The negativity or inconclusiveness of the reports obtained by coreneedle 
biopsy regarding diagnosis and grading may be due to learning curve during 
this study. 
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AGE & SEX WISE DISTRIBUTION OF 
VARIOUS MESENCHYMAL TUMOURS 
IN THIS STUDY 
S.NO Name of Tumour Total 
No. 
Male Female Age 
Group 
% 
1 
2 
 
3 
4 
 
5 
6 
7 
8 
 
9 
10 
 
11 
 
12 
Chondrosarcoma 
Malignant Fibrous 
Histiocytoma 
Fibrosarcoma 
Aggressive 
Fibromatosis 
Synoviosarcoma 
Rhabdomyosarcoma 
Ewing’s sarcoma 
Malignant peripheral 
Nerve sheath tumours 
Angio sarcoma 
Malignant Hemangio- 
Pericytoma 
Malignat Hemangio- 
Endothelioma 
Desmoid Tumour 
6 
6 
 
4 
10 
 
6 
4 
1 
4 
 
3 
2 
 
2 
 
2 
5 
3 
 
2 
6 
 
4 
4 
0 
3 
 
2 
1 
 
1 
 
1 
2 
3 
 
2 
4 
 
2 
0 
1 
1 
 
1 
1 
 
1 
 
1 
40-50 
50-65 
 
40-60 
1-65 
 
30-60 
15-60 
15-20 
10-45 
 
30-45 
30-40 
 
30-40 
 
40-55 
12 
12 
 
8 
20 
 
12 
8 
2 
8 
 
6 
4 
 
4 
 
4 
 Total 50 32 18   
 In this sutdy Male patients outnumbered female patients in the ratio 
of 1.6:1 and aggressive fibromatorses were the commonest tumours. 
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REGIONWISE DISTRIBUTION OF VAIOURS MESENCHYMAL 
TUMOURS IN THIS STUDY 
S Name of Tumour Head & 
Neck 
Upper 
Extre. 
Lower 
Extre. 
Trunk 
Back & 
Perineum 
Abdomen total
  No % No % No % No % No % No 
1 
2 
 
3 
4 
 
5 
6 
 
7 
8 
 
9 
10 
 
11 
 
12 
 
Chondrosarcoma 
Malignant Fibrous 
Histiocytoma 
Fibrosarcoma 
Aggressive 
Fibromatosis 
Synoviosarcoma 
Rhabdo 
myosarcoma 
Ewing’s sarcoma 
Malignant peripheral 
Nerve sheath tumours 
Angio sarcoma 
Malignant Hemangio- 
Pericytoma 
Malignat Hemangio- 
Endothelioma 
Desmoid Tumour 
- 
- 
 
- 
2 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
 
- 
- 
- 
 
- 
20
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
 
- 
- 
- 
2 
 
- 
- 
 
2 
1 
 
- 
- 
 
1 
- 
 
- 
 
- 
- 
33.3
 
- 
- 
 
33.3
25 
 
- 
- 
 
33.3
- 
 
- 
 
- 
2 
2 
 
3 
8 
 
4 
1 
 
- 
4 
 
2 
1 
 
- 
 
- 
33.3
33. 
 
75 
80 
 
66.7
25 
 
- 
100
 
66.7
50 
 
- 
 
- 
4 
1 
 
1 
- 
 
- 
2 
 
1 
- 
 
- 
1 
 
2 
 
- 
66.7 
16.4 
 
25 
- 
 
- 
50 
 
100 
- 
 
- 
50 
 
100 
 
- 
- 
1 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
 
2 
- 
16.6 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
 
100 
6 
6 
 
4 
10 
 
6 
4 
 
1 
4 
 
3 
2 
 
2 
 
2 
 Total 2 4 6 12 27 54 12 24 3 6 50 
In this study tumours encountered commonly in lower extremities 
followed by trunk, upper extremities, abdomen and Head and Neck. 
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CONCLUSION 
1. The demographic data of this study correlates well with the data 
observed by other studies. 
2. open biopsy / post excisional biopsy forms the gold standard in 
establishing the diagnosis and grading of the tumour. 
3. Coreneedle biopsy have higher value in establishing the diagnosis, 
compared to FNAC. 
4. FNAC could not give any information regarding grading of the tumour 
and coreneedle biopsy gave grading, with a rate very close to open or 
post excisional biopsy. 
5. Hence coreneedle biopsy can be accepted as the first line of investigation 
than FNAC for establishing the diagnosis and grading of mesenchymal 
tumours, on which the whole treatment planned upon. 
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SL.NO NAME AGE SEX SITE OF TUMOUR CLINICAL DIAG. GRADE FNAC
CORENEEDLE 
BIOPSY
OPEN BIOPSY 
POST OP. HPE 
1 Muthumani 30 F R. Chest wall Angiosarcoma II Inconclusive  Borderline  HET Grade II HET
2 Chockalingam 67 M L.Back Chondrosarcoma II Positive Grade I C S. Grade I C.S.
3 Sadayan 67 M R. Chest wall Fibrosarcoma III Negative Poorly diff M.H.P Grade III MHP
4 Sebastian 65 M Abdomen Fibrosarcoma III Positive Poorly diff. MFH Grade III MFH
5 Mokkammal 40 F Abdomen Desmoid tumour I Positive DFS DFS
6 Panchu 22 F L.Foot Synoviosarcoma III Positive Negative Grade III SS
7 Chinnasamy 42 M L.Hip Chondrosarcoma I Positive Well diff. CS Grade I C.S.
8 Sethuraja 32 M R. Gluteal region Fibrosarcoma III Negative Poorly diff . AS Grade III A.S
9 Dhanalakshmi 32 F L.Leg Synoviosarcoma I Negative Biphasic SS Grade I S.S
10 Perumal 60 M L.Forearm RMS III Positive Undiff. Sarcoma Grade III S.S
11 Muthukamatchi 58 M L. Chest wall Fibrosarcoma I Positive Well diff. FS Grade I F.S
12 Rajalakshmi 18 F L.Back Chondrosarcoma III Negative Round cell sarcoma Grade III E.S
13 Thangam 70 M R. Chest wall Fibrosarcoma I Positive Well diff. CS Grade I C.S.
14 Venugopal 50 M L. Shoulder Fibrosarcoma I Positive Well diff. M.F.H Grade I MFH
15 Pankajam 40 F R.Thigh Fibrosarcoma III Negative Poorly diff. FMS Grade III FS
16 Ramasamy 65 M L.Thigh Liposarcoma I Positive Well diff MFH Grade I MFH
17 Madhalai Karuppiah 38 M R.Thigh RMS III Negative Poorly diff. MPNST Grade III MPNST
18 Poormamuthu 14 M L.Hip Fibrosarcoma I Negative Well diff. FS Grade I MPNST
SL.NO NAME AGE SEX SITE OF TUMOUR CLINICAL DIAG. GRADE FNAC
CORENEEDLE 
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19 Karutha Oyyan 60 M L.Forearm Fibrosarcoma III Positive High grade RMS Grade III RMS
20 Thiagarajan 16 M R.Chestwall RMS III Positive Well diff. RMS Grade III RMS
21 Doulath Begam 19 F L.Thigh Fibrosarcoma - Negative AF AF
22 Anandhavalli 30 F R.Thigh Fibrosarcoma - Negative AF AF
23 Kadirvel 30 M L.Hip Angiosarcoma III Inconclusive  Poorly diff. MHP Grade III MHP
24 Nagaraj 31 M L.Leg Fibrosarcoma - Negative AF AF
25 Rakku 45 F L.Chestwall Chondrosarcoma I Positive Well diff. CS Grade ICS
26 Anusuya 1 F R.Gluteal region Fibrosarcoma - Negative AF AF
27 Murugan 40 M L.Back Fibrosarcoma II Negative Borderline MHE Gr. II MHE
28 Adam Baba 65 M R.Face Fibrosarcoma - Negative AF AF
29 Palaniammal 59 F L.Thigh Fibrosarcoma III Positive Poorly diff. MFH Gr. III MFH
30 Ramasamy 55 M Ant. Abd.Wall Desmoid tumour I Positive Well diff. DFS Gr. I DFS
31 Jeeva 32 M R.Leg Synoviosarcoma II Positive Borderline SS Gr. II SS
32 Senthil 34 M R. Shoulder Synoviosarcoma III Negative Negative Gr. III SS
33 Thayalan 52 M L. Back Chondrosarcoma I Positive Well Diff.CS Gr.I CS
34 Riaz 45 M R.Arm Fibrosarcoma III Negative Poorly diff AS Gr III AS
35 Pandian 48 M R.Leg Fibrosarcoma I Positive Well diff. FS Gr I AS
36 Shanmugam 45 M R.Gluteal region RMS III Positive Poorly diff, SS Gr. III SS
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37 Pappammal 50 F L.Foot Fibrosarcoma I Positive Well diff, FS Gr. I FS
38 Otchathevar 50 M R.Hip Fibrosarcoma I Positive Well diff, CS Gr. I CS
39 Balu 30 M R.Thigh Chondrosarcoma III Negative Round cell sarcoma Gr.III RMS
40 Sudha 28 F R.Thigh Fibrosarcoma - Negative AF AF
41 Ramachandran 36 M L.Neck Fibrosarcoma - Negative AF AF
42 Rakkammal 62 F R.Leg Fibrosarcoma I Positive Well diff, MFH Gr. I MFH
43 Krishnasamy 38 M L.Gluteal region Fibrosarcoma - Negative AF AF
44 Santhi 42 F L.Leg RMS III Negative Poorly diff. AS Gr. III AS
45 Lakshmi 37 F L.Thigh RMS III Negative Poorly diff. MPNST Gr. III MPNST
46 Raja 40 M R.Thigh Fibrosarcoma - Negative AF AF
47 Sundarammal 54 F R.Back Liposarcoma I Positive Well diff. M.F.H Gr. I MFH
48 Gopal 51 M L.Leg Fibrosarcoma - Negative Negative AF
49 Ramesh 22 M R.Back RMS III Positive High grade RMS Gr. III RMS
50 Dinesh 19 M R.Gluteal region Neurofibroma I Negative Negative Gr. I NFS
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